Partial restoration of CD20 protein expression and rituximab sensitivity after treatment with azacitidine in CD20-negative transformed diffuse large B cell lymphoma after using rituximab

MeSH terms

• Antigens, CD20 / biosynthesis*
• Antigens, CD20 / genetics
• Antigens, Neoplasm / biosynthesis*
• Antigens, Neoplasm / genetics
• Antimetabolites, Antineoplastic / pharmacology
• Antimetabolites, Antineoplastic / therapeutic use*
• Antineoplastic Combined Chemotherapy Protocols / administration & dosage
• Antineoplastic Combined Chemotherapy Protocols / adverse effects
• Antineoplastic Combined Chemotherapy Protocols / therapeutic use
• Azacitidine / pharmacology
• Azacitidine / therapeutic use*
• Bendamustine Hydrochloride / administration & dosage
• Combined Modality Therapy
• Cyclophosphamide / administration & dosage
• Cyclophosphamide / adverse effects
• Cytarabine / administration & dosage
• Dexamethasone / administration & dosage
• Doxorubicin / administration & dosage
• Doxorubicin / adverse effects
• Drug Resistance, Neoplasm
• Etoposide / administration & dosage
• Fatal Outcome
• Gene Expression Regulation, Neoplastic / drug effects*
• Humans
• Lymphoma, Follicular / drug therapy
• Lymphoma, Large B-Cell, Diffuse / chemically induced
• Lymphoma, Large B-Cell, Diffuse / drug therapy*
• Lymphoma, Large B-Cell, Diffuse / genetics
• Lymphoma, Large B-Cell, Diffuse / metabolism
• Male
• Middle Aged
• Molecular Targeted Therapy*
• Myelodysplastic Syndromes / chemically induced
• Myelodysplastic Syndromes / drug therapy*
• Neoplasms, Second Primary / chemically induced
• Neoplasms, Second Primary / drug therapy*
• Neoplasms, Second Primary / genetics
• Neoplasms, Second Primary / metabolism
• Prednisone / administration & dosage
• Prednisone / adverse effects
• Rituximab / administration & dosage
• Rituximab / pharmacology
• Rituximab / therapeutic use*
• Vincristine / administration & dosage
• Vincristine / adverse effects